GE Healthcare, a unit of General Electric Company, and CytoGenix, Inc. have entered into a supply agreement in which GE Healthcare will provide CytoGenix with DNA production reagents for use in the manufacture of vaccines and therapeutic compounds by CytoGenix.
Under the terms of the agreement, GE Healthcare has agreed that CytoGenix will be its exclusive customer for these reagents where the intended application is the manufacture of therapeutic compounds using CytoGenix' proprietary processes.
CytoGenix' proprietary synDNA™ is a cell-free production process that is designed to enable an efficient manufacturing cycle than extraction of DNA from bacterial fermentation.
CytoGenix expects to begin production of commercial-scale amounts of synDNA™ in April and continue development of DNA vaccines and therapeutic products against infectious diseases (herpes infections, multi-drug resistant bacterial infections), inflammatory disorders (psoriasis) and cancer.
"This guaranteed source of GMP grade reagents is vital to our product development especially for our pandemic and bioterrorism vaccine program," said Dr. Malcolm Skolnick, CytoGenix, Inc. President and CEO.
"We are very pleased to enter into this agreement with GE Healthcare and look forward to working with them to expand the development of DNA-based pharmaceuticals," added Dr. Skolnick.
"We believe CytoGenix can effectively utilize GE's innovative disease research technologies with its own ground-breaking research to ultimately enhance the efficiency of healthcare delivery and increase the breadth of options for patient care," said Carl W. Fuller, Ph.D., Vice President Science Fellow at GE Healthcare.